Menu Search
Equities

Magle Chemoswed Holding AB

52X:MUN

Magle Chemoswed Holding AB

Actions
  • Price (EUR)3.30
  • Today's Change0.000 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 07:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

  • Revenue in SEK (TTM)206.19m
  • Net income in SEK16.75m
  • Incorporated2012
  • Employees78.00
  • Location
    Magle Chemoswed Holding ABAgneslundsvagen 27MALMO 212 15SwedenSWE
  • Phone+46 40383300
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MAGLE:STO since
announced		Transaction
value
Amniotics AB (publ)Deal withdrawn22 Mar 202422 Mar 2024Deal withdrawn28.47%1.05m
Data delayed at least 15 minutes, as of Nov 06 2024 09:47 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.